Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.
2.

Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.

van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD.

Mol Cancer Ther. 2002 Jun;1(8):575-83.

3.

A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype.

van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD.

Clin Cancer Res. 1999 Sep;5(9):2511-9.

4.

A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells.

Wang L, Yang L, Luo Y, Zheng Y.

J Biol Chem. 2003 Nov 7;278(45):44617-25.

5.

Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.

Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL.

Breast Cancer Res Treat. 2006 Feb;95(3):219-28.

6.

RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells.

Wu M, Wu ZF, Kumar-Sinha C, Chinnaiyan A, Merajver SD.

Breast Cancer Res Treat. 2004 Mar;84(1):3-12.

7.

RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.

van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD.

Neoplasia. 2000 Sep-Oct;2(5):418-25.

8.

WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer.

Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF, Merajver SD.

Breast Cancer Res. 2004;6(1):R110-5.

9.

[Correlation of expression of RhoC with invasiveness of breast cancer cells in vitro].

Yuan Z, Su J, You JF, Wang JL, Cui XL, Zheng J.

Zhonghua Zhong Liu Za Zhi. 2007 Dec;29(12):898-903. Chinese.

PMID:
18478927
10.

Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.

Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM.

Breast Cancer Res. 2007;9(6):R76.

11.

WISP3 is a novel tumor suppressor gene of inflammatory breast cancer.

Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, Livant D, Merajver SD.

Oncogene. 2002 May 9;21(20):3172-80.

12.

Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo.

Pillé JY, Denoyelle C, Varet J, Bertrand JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C, Soria C, Li H.

Mol Ther. 2005 Feb;11(2):267-74.

13.

Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and nm23.

Tseng YH, Vicent D, Zhu J, Niu Y, Adeyinka A, Moyers JS, Watson PH, Kahn CR.

Cancer Res. 2001 Mar 1;61(5):2071-9.

14.

ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells.

Schedin PJ, Eckel-Mahan KL, McDaniel SM, Prescott JD, Brodsky KS, Tentler JJ, Gutierrez-Hartmann A.

Oncogene. 2004 Mar 4;23(9):1766-79.

PMID:
14767472
15.

Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer.

van Golen KL, Bao LW, Pan Q, Miller FR, Wu ZF, Merajver SD.

Clin Exp Metastasis. 2002;19(4):301-11.

16.

RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.

Kleer CG, Griffith KA, Sabel MS, Gallagher G, van Golen KL, Wu ZF, Merajver SD.

Breast Cancer Res Treat. 2005 Sep;93(2):101-10.

17.

Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy.

Pan Q, Bao LW, Kleer CG, Sabel MS, Griffith KA, Teknos TN, Merajver SD.

Cancer Res. 2005 Sep 15;65(18):8366-71.

18.

Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers.

Wu M, Wu ZF, Rosenthal DT, Rhee EM, Merajver SD.

Cancer. 2010 Jun 1;116(11 Suppl):2768-82. doi: 10.1002/cncr.25181.

19.

[Correlation of expression of RhoC with invasiveness of prostate cancer cell line PC-3M in vitro].

Yuan Z, Su J, You JF, Wang JL, Cui XL, Zheng J.

Zhonghua Yi Xue Za Zhi. 2008 Jan 1;88(1):51-5. Chinese.

PMID:
18346381
20.

R-Ras promotes tumor growth of cervical epithelial cells.

Rincón-Arano H, Rosales R, Mora N, Rodriguez-Castañeda A, Rosales C.

Cancer. 2003 Feb 1;97(3):575-85.

Items per page

Supplemental Content

Support Center